Lexaria Bioscience Corp (LEXX)

$0.77 -0.03 (-3.31%)
Market Cap 19.50M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 117,800
Avg Vol 718,904
Day's Range N/A - N/A
Shares Out 24.89M
Stochastic %K 57%
Beta 0.63
Analysts Strong Sell
Price Target $4.50

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
hovian
hovian Feb. 3 at 7:26 PM
$LEXX is just 70k us$ traded tday. when u see 500k or 2 MM plus volune there we gonna see action in motion. now is just a big siesta
0 · Reply
Turbofueled
Turbofueled Feb. 3 at 7:04 PM
$LEXX Ready for the Shake out??
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 6:18 PM
$LEXX Afternoon volume breakout again?
0 · Reply
Boston7452
Boston7452 Feb. 3 at 5:49 PM
$LEXX The offering may have been at 1.41 but it was done with hedge funds that love to short and harvest cost basis to reduce tax liability. Thus they like higher prices to short from...just not too high.
1 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 3 at 5:36 PM
$LEXX Its 8K SIR, company is fully funded through 2026...you can spew your bs, but thats the facts and the offering was at 1.41.
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 5:11 PM
$LEXX $NFTG $PHOE
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 5:07 PM
$LEXX After $NVO results it’s pretty clear they need DHT
0 · Reply
Boston7452
Boston7452 Feb. 3 at 4:42 PM
$LEXX Mgmt quest is to deliver exciting and transformative returns for Lexaria Stakeholders. While "stakeholders" the way mgmt means it may not include retail shareholders, it could.
1 · Reply
harlem111
harlem111 Feb. 3 at 4:23 PM
$LEXX Suppose I offer to buy a share for $1.01
1 · Reply
Boston7452
Boston7452 Feb. 3 at 4:05 PM
$LEXX Not creating fear, people should know it coming so its not a surprise. Also, in 2023 mgmt filed to have shareholders vote on a RS within 2 months of receiving notification (June 2023 - August 2023).
1 · Reply
Latest News on LEXX
Lexaria Awarded Six Additional Patents

Jan 22, 2026, 9:20 AM EST - 12 days ago

Lexaria Awarded Six Additional Patents

Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 22 days ago

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 5 weeks ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Dec 23, 2025, 12:06 PM EST - 6 weeks ago

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

NVO

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 6 weeks ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:00 PM EST - 7 weeks ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 7 weeks ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 2 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 4 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 4 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 4 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 4 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 5 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 6 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 6 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 6 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 8 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 8 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 8 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 9 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 10 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 10 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 10 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 10 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 10 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 11 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 11 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 1 year ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 1 year ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 1 year ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

hovian
hovian Feb. 3 at 7:26 PM
$LEXX is just 70k us$ traded tday. when u see 500k or 2 MM plus volune there we gonna see action in motion. now is just a big siesta
0 · Reply
Turbofueled
Turbofueled Feb. 3 at 7:04 PM
$LEXX Ready for the Shake out??
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 6:18 PM
$LEXX Afternoon volume breakout again?
0 · Reply
Boston7452
Boston7452 Feb. 3 at 5:49 PM
$LEXX The offering may have been at 1.41 but it was done with hedge funds that love to short and harvest cost basis to reduce tax liability. Thus they like higher prices to short from...just not too high.
1 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 3 at 5:36 PM
$LEXX Its 8K SIR, company is fully funded through 2026...you can spew your bs, but thats the facts and the offering was at 1.41.
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 5:11 PM
$LEXX $NFTG $PHOE
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 5:07 PM
$LEXX After $NVO results it’s pretty clear they need DHT
0 · Reply
Boston7452
Boston7452 Feb. 3 at 4:42 PM
$LEXX Mgmt quest is to deliver exciting and transformative returns for Lexaria Stakeholders. While "stakeholders" the way mgmt means it may not include retail shareholders, it could.
1 · Reply
harlem111
harlem111 Feb. 3 at 4:23 PM
$LEXX Suppose I offer to buy a share for $1.01
1 · Reply
Boston7452
Boston7452 Feb. 3 at 4:05 PM
$LEXX Not creating fear, people should know it coming so its not a surprise. Also, in 2023 mgmt filed to have shareholders vote on a RS within 2 months of receiving notification (June 2023 - August 2023).
1 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 3:58 PM
$LEXX Average financing raise in 2025 was $1.31 with 7m raised. Should worry anyone to be accumulating sub $1 especially with $UBS taking a huge stake here 👀
0 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 3 at 3:44 PM
$LEXX Why creating any fear if or when they get a letter for Nasdaq requirements for $1 minimum bid...We all know they will get a 6 month extension at worse....Also the price can shoot about $1 in literally a few minutes and stay there...Remember $1.41 was the last offering price that in the 8K said will fund the company through 2026. Very little risk here...been adding for weeks.
0 · Reply
Turbofueled
Turbofueled Feb. 3 at 3:43 PM
$LEXX This is Exactly the kind of setup that frustrates people before it moves!! 🌋🌋🌋🌋🌋🌋🌋🌋 $LEXX Going to Explode!
0 · Reply
The_Wealth_Maker
The_Wealth_Maker Feb. 3 at 3:41 PM
$LEXX
0 · Reply
Turbofueled
Turbofueled Feb. 3 at 3:37 PM
$LEXX statistically this is a VERY favourable!!! Lets go $LEXX
0 · Reply
Boston7452
Boston7452 Feb. 3 at 3:25 PM
$LEXX keep watching as Lexx is trading at 1/100 its potential value.
1 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 2:38 PM
$LEXX IMO notice from Nasdaq will be released during trading hours today. It will likely cause a SURGE in volume. Hold on to your pants
1 · Reply
Turbofueled
Turbofueled Feb. 3 at 2:01 PM
$LEXX All Eyes on $LEXX 🌋🌋🌋🌋🌋🌋🌋🌋🚀🚀🚀🚀🚀🚀🚀 Getting ready to explode!!! $NVO $TEVA $LLY $MRK
0 · Reply
Turbofueled
Turbofueled Feb. 3 at 1:10 PM
$LEXX
0 · Reply
Makingmillions192
Makingmillions192 Feb. 3 at 2:57 AM
$TEVA Going to buy out $LEXX
0 · Reply
Boston7452
Boston7452 Feb. 3 at 2:42 AM
$LEXX what this doesnt show is news regarding nasdaq deficiency is forthcoming and what impact that may have. Hopefully minimal negative impact as things could play out like in 2023.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 1:56 AM
$LEXX RSI: 52.67, MACD: -0.0039 Vol: 0.04, MA20: 0.76, MA50: 0.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply